Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton Sells 83,660 Shares

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 83,660 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the transaction, the chief executive officer now owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Stock Performance

Shares of BDSX stock opened at $0.94 on Thursday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The firm has a market capitalization of $136.74 million, a price-to-earnings ratio of -2.41 and a beta of 1.06. Biodesix, Inc. has a one year low of $0.86 and a one year high of $2.04. The company has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.49.

Institutional Trading of Biodesix

Several institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its position in shares of Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after buying an additional 21,179 shares during the period. HighTower Advisors LLC increased its stake in Biodesix by 17.1% during the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock worth $236,000 after acquiring an additional 22,500 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Biodesix in the 3rd quarter worth about $262,000. Stephens Inc. AR acquired a new position in shares of Biodesix in the 4th quarter valued at about $303,000. Finally, Geode Capital Management LLC lifted its stake in shares of Biodesix by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after purchasing an additional 22,623 shares in the last quarter. 20.96% of the stock is owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.